



# 16<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON **THROMBOEMBOLISM**

16-17 OCTOBER 2009, THE QUEEN ELIZABETH II CONFERENCE CENTRE, LONDON, UK

**Venous Thromboembolism**

**Cancer-Associated Thrombosis**

**Arterial Disease**

**Difficult Clinical Situations**

**Atrial Fibrillation**

**MEET THE EXPERT SESSIONS**

**WORKSHOPS**

**DEBATES**

**MULTIDISCIPLINARY FACULTY**



For updated programme information see [www.tri-london.ac.uk](http://www.tri-london.ac.uk)



# 16<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON THROMBOEMBOLISM

THE CONTINUING CHALLENGE OF THROMBOEMBOLIC DISEASE

Day One

Friday 16 October 2009

**12.45 – 14.00**

**Lunch**

---

**14.00 – 14.05**

**Welcome**

---

*A.K. Kakkar, UK*

**14.05 – 15.30**

**Plenary Session I**

---

**Challenges in Venous Thromboembolism**

*Co-Chairmen: G. Agnelli, Italy; V.V. Kakkar, UK*

Prevention of VTE

*A.G.G. Turpie, Canada*

Treatment of VTE

*P. Prandoni, Italy*

Update on pulmonary embolism

*R. Hull, Canada*

**15.30 – 16.00**

**Tea**

---

**16.00 – 17.30**

**Plenary Session II**

---

**Cancer-Associated Thrombosis**

*Co-Chairmen: H. Büller, The Netherlands; M. Levine, Canada*

Who is at risk?

*C. Francis, USA*

Prevention of cancer-associated thrombosis

*G. Agnelli, Italy*

Antithrombotic therapy – biological implications

*A.K. Kakkar, UK*



# 16<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON THROMBOEMBOLISM

## THE CONTINUING CHALLENGE OF THROMBOEMBOLIC DISEASE

Day Two

Saturday 17 October 2009

09.00 – 10.00

### Meet the Expert Sessions

---

1. Novel antithrombotic agents – will they change my practice?  
*H. Bounameaux, Switzerland*
2. Laboratory haemostasis – what's new?  
*A. Falanga, Italy*
3. Clinical trials in VTE – what is relevant?  
*C. M. Samama, France*
4. Biosimilar Heparins  
*J. Harenberg, Germany*

10.00 – 10.15

### Coffee

---

10.15 – 12.45

### Workshops

---

#### 1. Difficult Clinical Situations

*Co-Chairmen: H. Bounameaux, Switzerland; V.V. Kakkar, UK*

- i. The obese patient  
*S. Haas, Germany*
- ii. Renal impairment  
*R. Bauersachs, Germany*
- iii. Pregnancy  
*P. Prandoni, Italy*

#### 2. Atrial Fibrillation

*Co-Chairmen: R. Hull, Canada; J. Shepherd, Scotland*

- i. What is the role of anti-platelet therapy?  
*A.G.G. Turpie, Canada*
- ii. Modifying risk factors to improve outcomes – what is the evidence?  
*G.Y.H. Lip, UK*

#### 3. Cancer

*Co-Chairmen: A. Falanga, Italy; M.M. Samama, France*

- i. Incidental pulmonary embolism should be treated  
**Yes:** *A. Falanga, Italy*  
**No:** *C. Francis, USA*
- ii. Chemotherapy patients should receive routine thromboprophylaxis  
**Yes:** *C. Kessler, USA*  
**No:** *M. Levine, Canada*



# 16<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON THROMBOEMBOLISM

THE CONTINUING CHALLENGE OF THROMBOEMBOLIC DISEASE

Day Two

Saturday 17 October 2009

12.45 – 14.00

Lunch

14.00 – 15.30

Plenary Session III

---

**Arterial Disease**

*Co-Chairmen: S. Haas, Germany; A.G.G. Turpie, Canada*

Antithrombotic therapy for secondary prevention of coronary artery disease  
*F. Verheugt, The Netherlands*

Atrial Fibrillation: what's new – what can we expect?  
*G.Y.H. Lip, UK*

How should we use statins in 2009?  
*J. Shepherd, Scotland*

15.30 – 16.15

Debate

---

**Should low-molecular-weight heparins be given to all cancer patients to prolong survival?**

*Chairman: A.K. Kakkar, UK*

**Yes:** *H. Büller, The Netherlands*

**No:** *M. Levine, Canada*

16.15 – 16.30

Closing Remarks

---

*S. Haas, Germany*



Organised under the auspices of the Thrombosis Research Institute, London, United Kingdom and supported by an unrestricted educational grant from Bristol-Myers Squibb, Eisai Inc and Pfizer.